HCM:NGS-Hutchison China MediTech Limited

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 32.93

Change

0.00 (0.00)%

Market Cap

USD 4.38B

Volume

0.03M

Yahoo Analyst Target

USD 42.50 (29.06%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

N/A

STA Verdict

Verdict

About

Hutchison China Meditech Ltd is a biopharmaceutical company. The Company along with its subsidiaries is engaged in researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-04-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
MYL Mylan N.V.

N/A

USD 20.96B
GWPH GW Pharmaceuticals Plc

N/A

USD 3.74B
IRWD Ironwood Pharmaceuticals Inc.

N/A

USD 2.61B
SUPN Supernus Pharmaceuticals Inc.

N/A

USD 2.50B
AKRX Akorn Inc.

N/A

USD 2.47B
HZNP Horizon Pharma plc

N/A

USD 2.26B
HRTX Heron Therapeutics Inc.

N/A

USD 2.20B
MDCO The Medicines Company

N/A

USD 2.16B
AERI Aerie Pharmaceuticals Inc.

N/A

USD 2.12B
PAHC Phibro Animal Health Corporati..

N/A

USD 1.77B

ETFs Containing HCM

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.46% 28% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.46% 28% F 16% F
Trailing 12 Months  
Capital Gain 79.65% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.65% 90% A- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 55.17% 90% A- 95% A
Dividend Return 55.17% 90% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 63.94% 27% F 13% F
Risk Adjusted Return 86.28% 98% A+ 78% C+
Market Capitalization 1.51B 99% A+ 89% B+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -329.30 99% A+ 99% A+
Price/Book Ratio 23.03 9% F 4% F
Price / Cash Flow Ratio -106.23 100% A+ 99% A+
Price/Free Cash Flow Ratio -149.68 95% A 97% A+
Management Effectiveness  
Return on Equity -5.93% 71% C- 36% F
Return on Invested Capital -36.83% 54% F 20% F
Return on Assets -3.74% 80% B- 37% F
Debt to Equity Ratio 20.00% 53% F 68% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

HCM:NGS-Hutchison China MediTech Limited

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 32.93

Change

0.00 (0.00)%

Market Cap

USD 4.38B

Volume

0.03M

Yahoo Analyst Target

USD 42.50 (29.06%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

N/A

STA Verdict

Verdict

Values as of: 2018-04-21